Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $23.0000 (3.56%) ($22.1000 - $23.3000) on Fri. Jul. 17, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.45% (three month average) | RSI | 75 | Latest Price | $23.0000(3.56%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.7% a day on average for past five trading days. | Weekly Trend | TGTX advances 6.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -3.225% in a week (0% probabilities). VIXM(-35%) VXX(-33%) UUP(-18%) DRIV(-4%) XLC(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.225% (StdDev 6.45%) | Hourly BBV | 0 () | Intraday Trend | 3.3% | | | |
|
5 Day Moving Average | $22.47(2.36%) | 10 Day Moving Average | $22.73(1.19%) | 20 Day Moving Average | $21.06(9.21%) | To recent high | -4.8% | To recent low | 104.3% | Market Cap | $2.913b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |